1
|
Lundgaard I, Luzhynskaya A, Stockley JH, Wang Z, Evans KA, Swire M, Volbracht K, Gautier HOB, Franklin RJM, ffrench-Constant C, Attwell D, Káradóttir RT. Neuregulin and BDNF induce a switch to NMDA receptor-dependent myelination by oligodendrocytes. PLoS Biol 2013; 11:e1001743. [PMID: 24391468 PMCID: PMC3876980 DOI: 10.1371/journal.pbio.1001743] [Citation(s) in RCA: 256] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2013] [Accepted: 11/13/2013] [Indexed: 11/20/2022] Open
Abstract
Neuregulin switches oligodendrocytes between two modes of myelination: from a neuronal activity–independent mode to a myelin-increasing, neuronal activity–dependent, mechanism that involves glutamate release and NMDA receptor activation. Myelination is essential for rapid impulse conduction in the CNS, but what determines whether an individual axon becomes myelinated remains unknown. Here we show, using a myelinating coculture system, that there are two distinct modes of myelination, one that is independent of neuronal activity and glutamate release and another that depends on neuronal action potentials releasing glutamate to activate NMDA receptors on oligodendrocyte lineage cells. Neuregulin switches oligodendrocytes from the activity-independent to the activity-dependent mode of myelination by increasing NMDA receptor currents in oligodendrocyte lineage cells 6-fold. With neuregulin present myelination is accelerated and increased, and NMDA receptor block reduces myelination to far below its level without neuregulin. Thus, a neuregulin-controlled switch enhances the myelination of active axons. In vivo, we demonstrate that remyelination after white matter damage is NMDA receptor-dependent. These data resolve controversies over the signalling regulating myelination and suggest novel roles for neuregulin in schizophrenia and in remyelination after white matter damage. Myelination acts as an insulator for neurons and as such is essential for normal brain function, ensuring fast neuronal communication. Oligodendrocytes are the cells that wrap their membrane around nerve cell axons to form the myelin sheath that enables fast action potential propagation. However, what determines whether an individual axon becomes myelinated remains unknown. We show that there are two distinct modes of myelination: one that is independent of neuronal activity and the release of the neurotransmitter glutamate and another that depends on nerve cell action potentials releasing glutamate, which then activates a class of glutamate receptor (NMDA receptors) on oligodendrocyte lineage cells. We find that the protein neuregulin switches oligodendrocytes between these two modes of myelination; neuregulin increases oligodendrocyte lineage cells' sensitivity to glutamate by increasing the current flowing through their glutamate receptors. With neuregulin present, myelination is accelerated and increased. Blocking NMDA receptors reduces the amount of myelination to far below its level without neuregulin. Thus, a neuregulin-controlled switch enhances the myelination of active axons. We also demonstrate that remyelination after white matter damage (as occurs in diseases, such as spinal cord injury and multiple sclerosis) is NMDA receptor-dependent. These data help us understand the signalling that regulates myelination and suggest the possible involvement of neuregulin in schizophrenia and in remyelination after white matter damage.
Collapse
Affiliation(s)
- Iben Lundgaard
- Wellcome Trust–Medical Research Council (MRC) Stem Cell Institute, John van Geest Centre for Brain Repair, and Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
| | - Aryna Luzhynskaya
- Wellcome Trust–Medical Research Council (MRC) Stem Cell Institute, John van Geest Centre for Brain Repair, and Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
| | - John H. Stockley
- Wellcome Trust–Medical Research Council (MRC) Stem Cell Institute, John van Geest Centre for Brain Repair, and Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
| | - Zhen Wang
- Department of Pathology, University of Cambridge, Cambridge, United Kingdom
| | - Kimberley A. Evans
- Wellcome Trust–Medical Research Council (MRC) Stem Cell Institute, John van Geest Centre for Brain Repair, and Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
| | - Matthew Swire
- MRC Centre for Regenerative Medicine, Centre for Multiple Sclerosis Research, University of Edinburgh, Edinburgh, United Kingdom
| | - Katrin Volbracht
- Wellcome Trust–Medical Research Council (MRC) Stem Cell Institute, John van Geest Centre for Brain Repair, and Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
| | - Hélène O. B. Gautier
- Wellcome Trust–Medical Research Council (MRC) Stem Cell Institute, John van Geest Centre for Brain Repair, and Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
| | - Robin J. M. Franklin
- Wellcome Trust–Medical Research Council (MRC) Stem Cell Institute, John van Geest Centre for Brain Repair, and Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
| | - Charles ffrench-Constant
- MRC Centre for Regenerative Medicine, Centre for Multiple Sclerosis Research, University of Edinburgh, Edinburgh, United Kingdom
| | - David Attwell
- Department of Neuroscience, Physiology & Pharmacology, University College London, London, United Kingdom
| | - Ragnhildur T. Káradóttir
- Wellcome Trust–Medical Research Council (MRC) Stem Cell Institute, John van Geest Centre for Brain Repair, and Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
- * E-mail:
| |
Collapse
|
2
|
Abstract
Although glutamate was first hypothesized to be involved in the pathophysiology of schizophrenia in the 1980s, it was the demonstration that N-methyl-D-aspartate (NMDA) receptor antagonists, the dissociative anesthetics, could replicate the full range of psychotic, negative, cognitive, and physiologic features of schizophrenia in normal subjects that placed the "NMDA receptor hypofunction hypothesis" on firm footing. Additional support came from the demonstration that a variety of agents that enhanced NMDA receptor function at the glycine modulatory site significantly reduced negative symptoms and variably improved cognition in patients with schizophrenia receiving antipsychotic drugs. Finally, persistent blockade of NMDA receptors recreates in experimental animals the critical pathologic features of schizophrenia including downregulation of parvalbumin-positive cortical GABAergic neurons, pyramidal neuron dendritic dysgenesis, and reduced spine density.
Collapse
Affiliation(s)
- Joseph T. Coyle
- Department of Psychiatry and Neuroscience, Harvard Medical School, McLean Hospital, Belmont, MA,*To whom correspondence should be addressed; tel: 617-855-2101, fax: 617-855-2705, e-mail:
| |
Collapse
|